Psychiatric NP Scope of Practice for Weight Loss/GLP-1 in California

You’re a psychiatrist watching patients gain 40+ pounds on antipsychotics. Or you’re treating binge eating disorder and wondering if you can prescribe a GLP-1 alongside therapy. Maybe you’re considering adding weight management to your practice because half your patients ask about it.

The short answer: Yes, psychiatrists can legally prescribe weight-loss medications including GLP-1 agonists like semaglutide (Wegovy/Ozempic) and older drugs like phentermine. You hold an unrestricted medical license — obesity treatment is within your legal scope.

The real answer: It’s more complicated than that. State medical boards hold you to the same standard of care as any physician treating obesity, which means proper evaluations, documented follow-ups, and compliance with state-specific prescribing rules. And if you’re doing this via telehealth — which most weight-loss practices are now — you’re navigating a maze of DEA rules, state telehealth laws, and PDMP requirements that vary dramatically by state.

Let me walk you through what you actually need to know.

The Federal Telehealth Landscape: DEA Rules for Controlled Substances

Here’s the situation every prescriber needs to understand: under the Ryan Haight Online Pharmacy Act of 2008, federal law normally requires an in-person medical evaluation before you can prescribe controlled substances via telemedicine. This was designed to prevent internet ‘pill mills.’

During COVID, that requirement was waived. Psychiatrists could prescribe ADHD stimulants, benzodiazepines — and yes, controlled weight-loss medications like phentermine — to new patients via video without ever meeting them in person.

Current status (2026): The DEA and HHS just extended these telehealth flexibilities through December 31, 2026. This means you can continue prescribing controlled substances via telehealth nationwide without an initial in-person exam — but only until the end of 2026 or until new permanent rules are finalized.

The DEA is actively working on permanent regulations. Proposed rules include a ‘Special Registration’ pathway for telemedicine providers to prescribe Schedule III–V controlled substances remotely, and potential allowances for psychiatrists to prescribe Schedule II stimulants via telehealth with restrictions (like being licensed in the same state as the patient).

Bottom line: The clock is ticking. If you’re building a telehealth weight-loss practice around controlled substances, plan for a future where you’ll likely need either special DEA registration, periodic in-person visits, or both.

GLP-1s vs. Controlled Substances: A Critical Distinction

Here’s where it gets easier: GLP-1 agonists are NOT controlled substances. Semaglutide (Wegovy/Ozempic), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda) are freely prescribable via telehealth as long as you meet standard prescribing guidelines. No DEA registration required, no in-person exam mandated (federally).

Older weight-loss drugs are a different story:

• Phentermine (Adipex-P) – Schedule IV controlled substance
• Phentermine/topiramate (Qsymia) – Schedule IV
• Diethylpropion – Schedule IV

These fall under DEA rules. Right now you can prescribe them via telehealth (under the current extension), but you must:

• Hold a valid DEA registration
• Check your state’s Prescription Drug Monitoring Program (PDMP)
• Document a thorough evaluation
• Follow state-specific requirements (which we’ll get to)

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrist Scope of Practice: What the Rules Actually Say

No state requires a separate ‘obesity license’ to treat weight management. As an MD or DO, you can legally prescribe FDA-approved weight-loss medications or use drugs off-label for obesity treatment.

But — and this is important — medical boards expect you to practice competently within the standard of care. If a patient files a complaint or you’re audited, the question isn’t whether you have the ‘right’ to prescribe weight-loss meds. It’s whether you practiced at the level of a reasonably prudent physician treating obesity.

That means:

• Documenting BMI and comorbidities
• Ruling out endocrine causes (thyroid issues, etc.)
• Providing or referring for nutrition/exercise counseling
• Monitoring labs and vital signs appropriately
• Following up regularly (most states expect at least quarterly visits)
• Obtaining informed consent about risks

The Mental Health Intersection

As a psychiatrist, you have unique considerations. Many psychiatric medications cause weight gain — antipsychotics, mood stabilizers, some antidepressants. You’re already managing the metabolic consequences of your treatments.

Prescribing a GLP-1 or even phentermine to mitigate antipsychotic-induced weight gain is clinically rational. You just need to document your medical reasoning and monitor appropriately.

Phentermine presents special concerns for psychiatric patients:

• It’s a stimulant that can worsen anxiety
• May trigger mania in bipolar patients
• Contraindicated with MAOIs
• Can cause insomnia (which you’re probably already managing)

Many psychiatrists coordinate with primary care when prescribing weight-loss medications — either informal consultation or formal collaborative care. This isn’t legally required in most states, but it’s good medicine and covers you if questioned about practicing ‘outside your specialty.’

What About PMHNPs?

If you’re a Psychiatric-Mental Health Nurse Practitioner, your scope is different. PMHNPs are certified to treat mental health conditions. Prescribing purely for obesity may be viewed by state nursing boards as outside your scope unless:

• You’re working under a physician’s protocol that explicitly includes weight management
• You have additional certification in obesity medicine or family practice
• You’re in a state with full practice authority AND you can demonstrate competence

Some states (Texas, Florida, California) require that an NP’s collaborating physician be skilled in the specialty you’re practicing. A psychiatrist collaborating with a PMHNP might not satisfy state requirements for a weight-loss practice — you’d likely need a family medicine or endocrinology physician involved.

States with NP independent practice (California 2026, New York after 3,600 hours, Illinois with FPA) give experienced NPs more autonomy, but you’re still expected to practice within your training and refer appropriately.

State-Specific Rules: Where Things Get Complicated

Federal law sets the floor. States can — and do — add stricter requirements. Here’s what you need to know for key states:

Florida: Detailed Rules, Telehealth-Friendly (Mostly)

Florida explicitly allows telehealth for weight-loss treatment, but with specific requirements:

Patient eligibility (Florida Administrative Code 64B8-9.012):

• BMI ≥30 OR
• BMI ≥27 with obesity-related comorbidities OR
• Body fat >25% (men) / >30% (women)

Mandatory steps:

• Comprehensive initial evaluation (can be via telehealth)
• Written informed consent outlining medication risks
• Re-evaluation at least every 3 months while on treatment
• Provide each patient with Florida’s ‘Weight-Loss Consumer Bill of Rights’

Controlled substances: Florida prohibits teleprescribing Schedule II drugs EXCEPT for psychiatric treatment. This means:

• ✅ You CAN prescribe Adderall for ADHD via telehealth
• ❌ You CANNOT prescribe Schedule II appetite suppressants for weight loss via telehealth
• ✅ You CAN prescribe phentermine (Schedule IV) via telehealth for weight loss
• ✅ GLP-1s are fine via telehealth (not controlled)

Florida also requires checking the E-FORCSE PDMP before prescribing any controlled substance.

For PMHNPs in Florida: You need physician supervision unless you’ve attained autonomous practice status (currently available for Family NPs, not yet for Psych NPs as of 2025). The supervising physician should have appropriate expertise in obesity treatment.

California: Corporate Practice Minefield

California doesn’t prohibit telehealth prescribing of weight-loss meds, but the Corporate Practice of Medicine doctrine creates unique challenges.

Key requirements:

• Documented telehealth consent (B&P §2290.5) — must obtain and document at first encounter
• CURES PDMP check before first fill of any Schedule II–IV drug and every 4 months for ongoing therapy
• All prescriptions must be e-prescribed
• Telehealth exam can substitute for in-person IF it meets standard of care

The CPOM problem: Only physician-owned professional corporations can provide medical services in California. If you’re thinking about joining a telehealth weight-loss platform as a 1099 contractor, that platform better be physician-owned or structured through a compliant MSO model. Non-MDs can’t own or control medical practices.

NP rules: California NPs operate under ‘Standardized Procedures’ with physician supervision. As of 2026, experienced NPs (≥3 years, additional training) can attain independent practice under AB 890 — but only in their certified specialty. A Family NP could potentially run an independent weight-loss practice; a Psych NP would be on shakier ground.

Insurance reality: California’s Medi-Cal (Medicaid) will stop covering GLP-1 medications for weight loss effective January 2026. This means more cash-pay patients seeking telehealth options — but also more scrutiny from regulators watching for inappropriate prescribing.

New York: The In-Person Exam Requirement

New York is the strictest state for controlled substances. As of May 2025, NY Department of Health regulations (10 NYCRR §80.63) require at least one in-person medical evaluation before prescribing any controlled substance to a patient.

Limited exceptions:

• Another NY provider examined the patient in-person within the last 12 months and shared records
• You’re covering for a colleague who saw the patient in person
• Emergency situation with existing patient (5-day supply maximum)

This means in New York:

• ❌ You CANNOT start a new patient on phentermine via telehealth alone
• ✅ You CAN prescribe GLP-1s via telehealth (not controlled)
• ✅ You CAN continue controlled substances via telehealth for established patients you’ve seen in person

New York also requires:

• Checking the I-STOP PMP within 24 hours before prescribing any Schedule II–IV controlled substance
• All prescriptions must be e-prescribed (including non-controlled)

Many telehealth companies operating in NY either require an initial in-person visit or partner with local clinics to satisfy this requirement.

For PMHNPs in NY: After 3,600 hours of supervised practice, you can practice independently without a formal collaborative agreement. But treating obesity may still be viewed as outside your scope unless you have additional training or maintain informal physician collaboration.

Texas: Delegation Required for NPs/PAs

Texas allows telehealth prescribing of weight-loss medications (both GLP-1s and controlled substances like phentermine) as long as you establish a valid provider-patient relationship via live video.

Key requirements:

• Synchronous audiovisual interaction for initial evaluation (can’t just use a questionnaire)
• Check Texas PMP before prescribing controlled substances (mandatory for opioids/benzos, best practice for all)
• Send report to patient’s primary care physician within 72 hours if patient consents
• Document thorough evaluation meeting standard of care

NP/PA prescribing: Texas requires a Prescriptive Authority Agreement with a physician for all NP/PA prescribing. The agreement must explicitly include weight-loss medications if you plan to prescribe them.

NPs and PAs in Texas CANNOT prescribe Schedule II substances except in hospitals/hospice. But phentermine is Schedule IV, so it’s permitted under proper delegation.

Corporate practice: Texas prohibits non-physicians from owning medical practices. Weight-loss telehealth services must be physician-owned or use a compliant MSO structure.

Pennsylvania: Follow Federal Rules, Check PDMP

Pennsylvania has no comprehensive telehealth statute, so it largely defers to federal law and professional standards.

Current reality:

• Telehealth prescribing of controlled substances is permitted under the DEA extension
• No state-mandated in-person exam for weight-loss medications
• Must check PA PDMP before prescribing any opioid or benzodiazepine (each time), and before first prescription of other controlled substances

NP/PA requirements: Pennsylvania CRNPs and PAs need collaborative agreements with physicians to prescribe. The agreement must outline prescriptive authority for weight-loss medications.

No NP independent practice yet (legislation proposed but not passed as of 2025).

Illinois: Most Telehealth-Friendly

Illinois explicitly allows provider-patient relationships via telehealth and has Full Practice Authority for qualified APRNs.

What this means:

• No in-person exam required for telehealth prescribing (including controlled substances)
• Audio-only telehealth permitted in some cases (though video recommended for weight management)
• Experienced NPs (4,000+ hours, additional coursework) can practice and prescribe independently, including controlled substances

PDMP requirements: Must check Illinois PMPnow for each Schedule II narcotic prescription and every 90 days for ongoing opioid therapy. (Not mandated for stimulants/other controlled substances, but recommended.)

All controlled substance prescriptions must be e-prescribed as of January 2023.

Best environment for telehealth weight-loss practices among these states — relatively few barriers and strong parity laws for insurance coverage.

The Economics: Why Platforms Make Sense

Let’s talk about the business reality of DIY marketing versus joining a platform like Klarity.

If you decide to build your own telehealth weight-loss practice, here’s what patient acquisition actually costs:

SEO approach: 6–12 months of consistent investment before you see meaningful patient flow. You’ll need:

• Content creation ($2,000–5,000/month for quality)
• Technical SEO work ($3,000–8,000 upfront, $1,000+/month ongoing)
• Backlink building
• Local citations and directory listings
• Schema markup and site optimization

Total investment before your first organic patient: $15,000–50,000. And you need the expertise to do it right.

Google Ads: Mental health and weight-loss keywords cost $15–40+ per click. Realistic conversion rates mean you’re paying $200–400+ per booked patient once you factor in:

• Ad spend testing
• Click costs that don’t convert
• Landing page optimization
• Staff time to qualify leads
• No-show rates from cold leads

Directory listings (Psychology Today, Zocdoc, etc.):

• Monthly subscription fees ($200–500)
• Competition with hundreds of other providers
• Zocdoc charges $35–100+ per booking (on top of monthly fees)

Most solo providers end up spending $3,000–5,000/month on marketing with uncertain results.

The Klarity Model: Guaranteed ROI

Klarity uses a pay-per-appointment model. You pay a standard listing fee per new patient lead — but only when qualified patients actually book with you.

What you get:

• Pre-qualified patients already matched to your specialty and availability
• No upfront marketing spend or monthly subscription fees
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

Instead of gambling $3,000–5,000/month on marketing channels that might not work, you pay only for confirmed appointments. That’s guaranteed ROI versus DIY marketing risk.

For providers starting out or scaling up, a platform that handles patient acquisition removes the risk entirely. You focus on clinical care, not marketing expertise you don’t have.

Practical Steps: Staying Compliant

Whether you’re prescribing GLP-1s to mitigate medication side effects or building a dedicated weight-loss practice, here’s how to stay within the law:

1. Verify licensing for each stateCheck where your patient is physically located at each visit. You must be licensed in that state — no exceptions.

2. Document thorough evaluationsYour telehealth notes should include:

• Chief complaint and weight history
• Current BMI and comorbidities
• Prior weight-loss attempts (diet, exercise, other medications)
• Relevant medical history (cardiovascular, psychiatric, endocrine)
• Current medications and potential interactions
• Mental status exam (for psychiatric patients)
• Informed consent discussion
• Treatment plan including follow-up schedule

3. Check PDMPs religiouslyFor any controlled substance:

• California: CURES (first fill and every 4 months)
• Florida: E-FORCSE (every time)
• New York: I-STOP (within 24 hours before each prescription)
• Texas: Tx PMP (before prescribing)
• Pennsylvania: PA PDMP (before first fill, each time for opioids/benzos)
• Illinois: PMPnow (for Schedule II narcotics)

Document every check in your medical record.

4. Use e-prescribing for everythingMost states now require electronic prescribing for controlled substances. Many require it for all prescriptions.

5. Follow state-specific protocols

• Florida: Quarterly re-evaluations, written informed consent, Consumer Bill of Rights
• New Jersey: Psychiatric evaluation, diet/exercise counseling, endocrine workup
• Virginia: Physical exam, labs, 30-day follow-up

6. Coordinate careWhen possible, communicate with the patient’s primary care physician (with patient consent). This is required in some states (Texas within 72 hours) and best practice everywhere.

7. Stay current on regulationsThe DEA extension expires December 31, 2026. New permanent rules are coming. Subscribe to updates from:

• Your state medical board
• DEA DIVERSION newsletters
• Professional organizations (APA, ASAM, OMA)

FAQ

Can I prescribe Ozempic for weight loss via telehealth?

Yes, in most states. Semaglutide (Ozempic/Wegovy) is not a controlled substance, so it’s not subject to DEA’s in-person exam requirement. You must:

• Be licensed in the patient’s state
• Conduct a proper telehealth evaluation (usually video)
• Meet standard of care for obesity treatment
• Follow any state-specific requirements (like Florida’s quarterly follow-ups)

Do I need additional certification to prescribe weight-loss medications?

No legal requirement in most states, but it’s professionally prudent. Consider:

• American Board of Obesity Medicine (ABOM) certification
• CME courses in obesity medicine
• Training in GLP-1 prescribing and titration

This demonstrates competence if ever questioned and improves patient outcomes.

Can I prescribe phentermine without seeing the patient in person?

Depends on your state:

• New York: NO — requires in-person exam for controlled substances
• Florida, Texas, California, Pennsylvania, Illinois: YES (under current DEA extension through 2026)

Even where permitted, you must establish a valid provider-patient relationship via live video and check your state PDMP.

As a PMHNP, can I run a weight-loss practice?

Legally complicated. Your psychiatric NP certification covers mental health conditions, not obesity treatment. Options:

• Work under physician supervision with explicit protocol for weight management
• Obtain additional certification (Family NP or obesity medicine)
• Partner with a physician with appropriate expertise
• In states with full practice authority, you can practice independently BUT must stay within your competence — boards will scrutinize treating obesity if it’s outside your training

What labs should I order before prescribing weight-loss medications?

Standard practice includes:

• Comprehensive metabolic panel (kidney/liver function)
• Lipid panel
• Hemoglobin A1c or fasting glucose
• TSH (rule out hypothyroidism)
• Pregnancy test (for women of childbearing age)
• Consider EKG if prescribing stimulants (phentermine)

Some states mandate specific tests (e.g., New Jersey requires endocrine evaluation).

How often do I need to see weight-loss patients?

Minimum requirements vary:

• Florida: Every 3 months for medication management
• Virginia: Within 30 days of starting therapy
• Most states: Follow FDA-approved medication protocols (typically monthly initially, then quarterly once stable)

Best practice: monthly visits for first 3 months during titration, then every 1–3 months for ongoing management.

What happens when the DEA extension expires?

Current extension runs through December 31, 2026. Proposed permanent rules include:

• Special telemedicine registration for prescribing Schedule III–V remotely
• Possible allowance for psychiatrists to prescribe Schedule II via telehealth with restrictions
• Potential requirement for in-person visits for some controlled substances

Start planning now for hybrid models or special registration pathways.

Next Steps

If you’re a psychiatrist considering weight-loss prescribing:

Start small: Begin with patients where it makes clinical sense — antipsychotic-induced weight gain, binge eating disorder, patients asking about GLP-1s. Get comfortable with the medications and monitoring.

Get trained: Take CME courses in obesity medicine. Learn proper GLP-1 titration, side effect management, and when to refer.

Check your state rules: Review your state medical board’s telehealth requirements, PDMP mandates, and any obesity-specific regulations.

Document everything: Your medical records are your protection. Thorough documentation of evaluations, informed consent, monitoring, and follow-up demonstrates standard of care.

Consider platform partnerships: If you want to scale a weight-loss practice without the marketing headache, explore platforms like Klarity that handle patient acquisition and infrastructure.

The demand for weight management services is exploding. GLP-1 medications are transforming obesity treatment. As a psychiatrist, you’re uniquely positioned to serve patients dealing with both psychiatric and metabolic challenges — you just need to navigate the regulatory landscape carefully.

Want to explore joining Klarity’s provider network? We handle patient matching, telehealth infrastructure, and credentialing across multiple states — you focus on clinical care. Learn more about becoming a Klarity provider.

Sources and References

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,disruptions%20in%20care%20while%20permanent
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,FDA%2C%20pharmacy%2C%20and%20board%20alerts
• https://www.cchpca.org/topic/online-prescribing/#:~:text=No%20controlled%20substance%20shall%20be,for%20the%20medical%20evaluation%2C%20and
• https://florida.public.law/statutes/fla.stat.456.47#:~:text=provider%20is%20not%20required%20to,is%20prescribed%20for%20the%20following
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=Florida%20law%20restricts%20the%20prescribing,5
• https://www.ofdigitalinterest.com/2023/09/weight-loss-programs-in-florida-state-law-considerations-for-glp-1-telehealth-providers/#:~:text=2000%20%28Fla,loss%20providers%20are%20required%20to
• https://www.medicaldirectorco.com/california-weight-loss-clinic-and-telehealth-compliance-guide-2025/#:~:text=medical%20director%20and%20retain%20full,Clinics%20must%20maintain%20DEA
• https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/#:~:text=,require%20DEA%20registration
• https://www.fiercehealthcare.com/providers/primary-care-doctors-concerned-about-patient-risks-telehealth-prescribers-glp-1s-survey#:~:text=Primary%20care%20physicians%20are%20mainly,cited%20by%20half%20of%20physicians
• https://www.goodwinlaw.com/en/insights/publications/2024/03/alerts-lifesciences-hltc-changing-regulatory-reimbursement-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated